Skip to main content
Premium Trial:

Request an Annual Quote

Peter Wrighton-Smith

Inviata has appointed Peter Wrighton-Smith to its board of directors. He comes to Inviata's board with strategic product development and international commercialisation experience in addition to a broad understanding of the clinical service testing market. Wrighton-Smith is the current CEO and founder of Oxford Immunotec where he has overseen the company raise five rounds of venture funding prior to an IPO on NASDAQ in 2013.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.